Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose reduction strategy of bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed HIV-infected adults
2022-000358-26Phase 4Active
- Sponsor
- August Pi i Sunyer Biomedical Research Institute
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by August Pi i Sunyer Biomedical Research Institute. Primary endpoints: Virological efficacy at 4 weeks and Safety and tolerability. Started Mar 2022; status: active.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2022-000358-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000358-26.